Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 8/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525339 | 0.91 | SMO (0.80) | SMOMAPTHPGDTYK2 | |
| SCHEMBL4257560 | 0.86 | SMO (0.56) | SMONPC1RAB9AKDM4EMAPT | |
| SCHEMBL4259343 | 0.84 | SMO (0.63) | SMONPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL4257047 | 0.84 | SMO (0.66) | SMONPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4262096 | 0.84 | SMO (0.66) | SMONPC1RAB9AKDM4EMAPT | |
| SCHEMBL4263804 | 0.83 | SMO (0.74) | SMOKDM4EMAPTHPGD | |
| SCHEMBL4255817 | 0.81 | SMO (1.00) | SMOMAPTHPGDTYK2 | |
| SCHEMBL4254597 | 0.78 | SMO (0.85) | SMOMAPTHPGDTYK2 | |
| SCHEMBL4253028 | 0.76 | SMO (0.81) | SMOMAPTHPGD | |
| SCHEMBL4254933 | 0.72 | SMO (0.79) | SMONPC1RAB9AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | claimed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | OXA1L, CYP11B2, CYP3A7 | SMO 1063/4885NPC1 952/4885RAB9A 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.